Otis W. Brawley was named the Bloomberg Distinguished Professor of Oncology and Epidemiology at Johns Hopkins University.
In recent years, NCI spending on extramural research has been following the same trajectory as Congressional appropriations for the institute: up, up, up.
Amy Abernethy, a thought leader in the field of evidence generation and the development of real-world evidence, was named principal deputy commissioner at FDA.
The University of Alabama at Birmingham Comprehensive Cancer Center has received a $30 million gift from O'Neal Industries Inc., a family-owned global business based in Birmingham.
As Vitrakvi (larotrectinib) becomes the second drug to get FDA approval for a site-agnostic indication, physicians will have yet another reason to order sequencing, said David Hyman, chief of the Early Drug Development Service at Memorial Sloan Kettering Cancer Center and the principal investigator for a larotrectinib clinical trial that led to the approval.
Paul Goldberg spoke with Elizabeth Jaffee.
Paul Goldberg spoke with Samuel Waksal.
When cervical cancer patients were referred to MD Anderson Cancer Center for a prospective, phase III trial testing for noninferiority of minimally invasive vs. open abdominal radical hysterectomy, many requested the minimally invasive approach, because their referring physicians said it was better, said Pedro Ramirez, a professor of gynecologic oncology at MD Anderson.
Gynecologic oncologists need to reduce oncologic risk, but it's not going to happen without knowing why minimally invasive radical hysterectomies decrease survival of patients with cervical cancer, said Joshua Kesterson, chief of the Division of Gynecologic Oncology at Penn State Cancer Institute.
